$Effect of KIT Inhibition by Imatinib on Airway Mast Cells in Patients with Severe Refractory Asthma (KIA)$

Effect of KIT Inhibition by Imatinib on Airway Mast Cells in Patients with Severe Refractory Asthma (KIA)

Methods We conducted a randomized, double-blind, placebo-controlled, multi-center 24 week proof-of-principle trial of imatinib in severe asthmatics with persistent airway hyperresponsiveness (AHR) and poor asthma control despite maximal inhaled corticosteroid and long-acting beta-agonist therapy.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of allergy and clinical immunology 2017-02, Vol.139 (2), p.AB169-AB169
Hauptverfasser:	Cahill, Katherine N., MD, Katz, Howard, PhD, Cui, Jing, Lai, Juying, Kazani, Shamsah, MD, Crosby-Thompson, Allison, Garofalo, Denise, Castro, Mario, MD, Jarjour, Nizar N., MD, DiMango, Emily, MD, Erzurum, Serpil C, Trevor, Jennifer L, Shenoy, Kartik, MD, Chinchilli, Vernon M., PhD, Wechsler, Michael E., MD, Laidlaw, Tanya M., MD, FAAAAI, Israel, Elliot, MD, FAAAAI, Boyce, Joshua A., MD, FAAAAI
Format:	Artikel
Sprache:	eng
Schlagworte:	Airway management Allergies Allergy and Immunology Asthma Histamine Smooth muscle
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Methods We conducted a randomized, double-blind, placebo-controlled, multi-center 24 week proof-of-principle trial of imatinib in severe asthmatics with persistent airway hyperresponsiveness (AHR) and poor asthma control despite maximal inhaled corticosteroid and long-acting beta-agonist therapy.
ISSN:	0091-6749 1097-6825
DOI:	10.1016/j.jaci.2016.12.553